Moderna has dosed the first subjects in a Phase II clinical study with its modified Covid-19 vaccines designed to address the potential need for booster vaccine candidates.
Enrolment is being carried out by amending the ongoing Phase II clinical study.
A variant-specific booster candidate, mRNA-1273.351, encodes for prefusion stabilised SARS-CoV-2 variant B.1.351’s spike protein. This variant was first seen in the Republic of South Africa.
It is being evaluated as a booster vaccine to increase the extent of the response to emerging variants with key-receptor-binding domains (RBD) mutations.
A multivalent booster candidate, mRNA-1273.211 combines Moderna’s authorised vaccine mRNA-1273 against ancestral strains and mRNA-1273.351 in a single vaccine.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
It can potentially elicit a broad immune response as a primary series, as well as a booster to those who are already vaccinated with mRNA-1273.
According to the previously published data, vaccination with the Moderna Covid-19 vaccine produced neutralising titers against all key variants tested, including variants B.1.1.7 and B.1.351, with a six-times reduction in neutralising titers against B.1.351.
As a precautionary measure, the company is pursuing a clinical development strategy against the emerging variants.
An amendment to the Phase II study will have 60 subjects vaccinated with mRNA-1273 to receive a single booster dose of either 20µg of mRNA-1273.351 or 50µg of mRNA-1273.351 or 50µg of mRNA-1273.211.
In a previous protocol amendment, Phase II study subjects vaccinated with mRNA-1273 were given a single 50µg booster dose of mRNA-1273. Dosing in this protocol extension is progressing.
The National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) will also carry out a Phase I clinical trial at the same time.
This study will evaluate the monovalent and multivalent modified mRNA-1273 vaccines as a primary series in naïve people and as a booster vaccine in those vaccinated with mRNA-1273.
The institute will begin the study on obtaining safe-to-proceed authorisation from the US Food and Drug Administration.